Vimarsana
Biggest News Aggregation in the World

Mark Leiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Leiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Leiser Today - Breaking & Trending Today

BLOG: Predicting sinusoidal obstructive syndrome after allogeneic stem cell transplantation - Vimarsana News

BLOG: Predicting sinusoidal obstructive syndrome after allogeneic stem cell transplantation

Sinusoidal obstructive syndrome is a rare but potentially serious complication that can occur after hematopoietic stem cell transplantation.On average, incidence of sinusoidal obstructive syndrome (SOS) among adults is 10%. In severe cases, the mortality rate can be as high as 80%.

Source: healio.com
Brain Tumor Awareness Month: Novel treatments exceed expectations, CAR-Ts show promise - Vimarsana News

Brain Tumor Awareness Month: Novel treatments exceed expectations, CAR-Ts show promise

May is Brain Tumor Awareness Month.An estimated 25,400 new cases of malignant brain or spinal cord tumors will be diagnosed in the United States this year, according to American Cancer Society, and approximately 18,760 people will die of the disease.

Source: healio.com
BLOG: Nomenclature in GVHD — words matter - Vimarsana News

BLOG: Nomenclature in GVHD — words matter

Blogs | | For years now, transplant physicians have spoken different languages when referring to a matter of utmost relevance — graft-versus-host disease.Here is a practical example: If a patient with lower gastrointestinal acute GVHD with a volume of stools of 900 ml per day with bloody stools — without another explanatory cause — is scored according to the original Glucksberg criteria,

Source: healio.com
KEYNOTE-716: Primary melanoma, not lymph nodes, should 'drive therapeutic decision-making' - Vimarsana News

KEYNOTE-716: Primary melanoma, not lymph nodes, should 'drive therapeutic decision-making'

CHICAGO — Adjuvant pembrolizumab showed durable benefit vs. placebo among patients with resected stage IIB or IIC melanoma, according to randomized phase 3 study results presented at ASCO Annual Meeting.After more than 3 years of follow-up, patients assigned the anti-PD-1 therapy achieved significantly longer distant metastasis-free survival (DMFS) and RFS, results of the KEYNOTE-716 trial

Source: healio.com
Durvalumab regimens extend PFS in advanced endometrial cancer - Vimarsana News

Durvalumab regimens extend PFS in advanced endometrial cancer

The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.Chemotherapy is standard first-line treatment for women with advanced endometrial cancer; however, long-term outcomes remain poor and more effective treatment options are needed.

Source: healio.com